{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:55:52Z","timestamp":1777949752280,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is a lethal malignancy, with hepatitis B virus (HBV) infection as its leading cause in China. Transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) treatment was gradually applied in clinic, but the lack of targeted prognostic tools for this cohort remains a critical issue. This multicenter study aimed to develop a prognostic model for recurrence-free survival (RFS) in HBV-related HCC patients after the combined treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 604 patients from two hospitals were enrolled; 502 (Beijing You\u2019an Hospital) formed the training\/internal validation cohort (7:3 split), and 102 (Beijing Ditan Hospital) served as the external validation cohort. Baseline clinical, tumor, and laboratory data were collected. LASSO regression and random survival forest were used for variable screening, followed by multivariate Cox regression to identify independent predictors. The model was visualized as a nomogram, evaluated via Kaplan-Meier survival curves, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Age, tumor number, tumor size, gamma-glutamyl transferase (GGT), and total bilirubin (TBIL) were identified as independent RFS factors. The nomogram developed based on the five factors exhibited good discriminative ability: AUC values for 1-, 3-, 5-year RFS were 0.759, 0.777, 0.783 (training cohort), 0.708, 0.751, 0.714 (internal validation cohort), and 0.701, 0.708, 0.751 (external validation cohort). Kaplan-Meier curves confirmed significant RFS differences between high\/low-risk groups (all P&amp;lt;0.001), and DCA demonstrated positive net clinical benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study successfully developed a well-performed nomogram model to predict 1-, 3-, and 5-year RFS in HBV-related HCC patients following TACE combined with RFA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1760126","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:24:56Z","timestamp":1777868696000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic model for predicting recurrence-free survival in HBV-related hepatocellular carcinoma patients after combined treatment: a multicenter study"],"prefix":"10.3389","volume":"16","author":[{"given":"Bojun","family":"Liu","sequence":"first","affiliation":[{"name":"Interventional Therapy Center for Oncology, Beijing You\u2019an Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Yin","sequence":"additional","affiliation":[{"name":"National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Department of Infectious Disease, The Third Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenying","family":"Qiao","sequence":"additional","affiliation":[{"name":"National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Ding","sequence":"additional","affiliation":[{"name":"National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caixia","family":"Hu","sequence":"additional","affiliation":[{"name":"Interventional Therapy Center for Oncology, Beijing You\u2019an Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: New trends","volume":"72","author":"Singal","year":"2020","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2023.151","article-title":"Chinese expert consensus on the whole-course management of hepatocellular carcinoma (2023 edition)","volume":"14","author":"Yang","year":"2025","journal-title":"Liver Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003171","article-title":"Survey of hepatitis B virus infection for liver cancer screening in China: A population-based, cross-sectional study","volume":"137","author":"Xu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030666","article-title":"Management of hepatocellular carcinoma in 2024: The multidisciplinary paradigm in an evolving treatment landscape","volume":"16","author":"Kinsey","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i36.10327","article-title":"Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system","volume":"21","author":"Han","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2024.2331704","article-title":"Radiofrequency ablation of hepatocellular carcinoma guided by real-time physics-based ablation simulation: a prospective study","volume":"41","author":"Hoffer","year":"2024","journal-title":"Int J Hypertherm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.42.9936","article-title":"Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial","volume":"31","author":"Peng","year":"2013","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1673-8","article-title":"Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone","volume":"18","author":"Kim","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-288","article-title":"Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study","volume":"12","author":"Yan","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.01.010","article-title":"Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal","volume":"80","author":"Trevisani","year":"2024","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-025-10806-6","article-title":"Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma","volume":"19","author":"Rocco","year":"2025","journal-title":"Hepatol Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100747","article-title":"A deep learning model of histologic tumor differentiation as a prognostic tool in hepatocellular carcinoma","volume":"38","author":"Patil","year":"2025","journal-title":"Mod Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13931","article-title":"Application of least absolute shrinkage and selection operator logistic regression for the histopathological comparison of chondrodermatitis nodularis helicis and hyperplastic actinic keratosis","volume":"48","author":"Narala","year":"2021","journal-title":"J Cutan Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw145","article-title":"Random survival forest in practice: a method for modelling complex metabolomics data in time to event analysis","volume":"45","author":"Dietrich","year":"2016","journal-title":"Int J Epidemiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000517992","article-title":"The prognostic impact of tumor differentiation on recurrence and survival after resection of hepatocellular carcinoma is dependent on tumor size","volume":"10","author":"Shinkawa","year":"2021","journal-title":"Liver Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i12.1321","article-title":"Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models","volume":"24","author":"Wongjarupong","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.08.027","article-title":"Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection","volume":"69","author":"Chan","year":"2018","journal-title":"J Hepatol"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1016\/j.freeradbiomed.2023.09.020","article-title":"Targeting gamma-glutamyl transpeptidase: A pleiotropic enzyme involved in glutathione metabolism and in the control of redox homeostasis","volume":"208","author":"Mitri\u0107","year":"2023","journal-title":"Free Radic Biol Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12920-024-01856-0","article-title":"GGT5 facilitates migration and invasion through the induction of epithelial-mesenchymal transformation in gastric cancer","volume":"17","author":"Luo","year":"2024","journal-title":"BMC Med Genomics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03791-z","article-title":"Comprehensing the role of serum GGT in colorectal carcinoma: cancer risk, prognostic and diagnostic significance","volume":"27","author":"Anupam","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.22541\/au.174888412.28573283\/v1","article-title":"From gene to enzyme: Multidimensional decoding of the GGT molecular family and its clinical tumor diagnosis","volume":"14","author":"Wang","year":"2025","journal-title":"Cancer Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/liv.15099","article-title":"Gamma-glutamyl transferase (\u03b3-GT) - an old dog with new tricks","volume":"42","author":"Brennan","year":"2022","journal-title":"Liver Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1186\/s12876-025-04321-z","article-title":"Gamma-glutamyltransferase and the survival of hepatocellular carcinoma patients after transarterial chemoembolization: a meta-analysis and systematic review","volume":"25","author":"Huang","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000015603","article-title":"Prognostic and clinicopathological significance of gamma-glutamyltransferase in patients with hepatocellular carcinoma: A PRISMA-compliant meta-analysis","volume":"98","author":"Sun","year":"2019","journal-title":"Med (Balt)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s505328","article-title":"Prediction model of survival in unresectable HCC with central bile duct invasion receiving TACE after biliary drainage: TEMP score","volume":"12","author":"Fan","year":"2025","journal-title":"J Hepatocell Carcin"},{"key":"B30","article-title":"The multifaceted role of bilirubin in liver disease: A literature review","volume":"12","author":"Ram\u00edrez-Mej\u00eda","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/cmi.2015.109","article-title":"Presentation of hepatocellular antigens","volume":"13","author":"Grakoui","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.814155","article-title":"Impact of antigen presentation mechanisms on immune response in autoimmune hepatitis","volume":"12","author":"Fasano","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1760126\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:24:57Z","timestamp":1777868697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1760126\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1760126"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1760126","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"article-number":"1760126"}}